Left Ventricular Mass at MRI and Long-Term Risk of Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis (MESA) Left ventricular hypertrophy.

Slides:

Advertisements

Similar presentations

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:

Advertisements

Trial profile Fox K et al. Lancet 2008;372:

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.

From: Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study Ann Intern Med. 2015;163(5):

Volume 385, Issue 9985, Pages (June 2015)

All-cause mortality by treatment group

Copyright © 2006 American Medical Association. All rights reserved.

Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations Cardiology 2015;132: DOI: / Fig. 1. Semilogarithmic.

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Circ Cardiovasc Interv

Noriko Kikuchi et al. JACEP 2016;2:

Baseline characteristics of patients

Age-related cumulative incidence for (A) serious adverse events (including death, heart failure admission, ventricular arrhythmia and cardiac transplant)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Nat. Rev. Cardiol. doi: /nrcardio

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Johannes Steiner et al. JACC 2017;70:

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Figure 2 Absolute difference in seasonal peak

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.

Association between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Perfusion PET/CT Coronary microvascular.

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

Baseline Characteristics

Potential mechanisms whereby statins may reduce the risk of stroke

Volume 385, Issue 9985, Pages (June 2015)

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

Distribution of Cardiovascular Risk Factors by Baseline CRP Concentration M. Cushman et al. Circulation. 2005;112:25-31.

Baseline Characteristics of the Study Participants

(A) Meta-analysis of repeat revascularisation in randomised trials.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Baseline Characteristics of the Subjects*

Deep Learning for Diagnosis of Chronic Myocardial Infarction on Nonenhanced Cardiac Cine MRI Deep learning to identify myocardial infarction on nonenhanced.

Collet JP, et al. Lancet 2009;373:309-17

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Long-term results estimates for patients with anomalous origin of coronary artery from the pulmonary artery, showing survival, freedom from coronary and.

Associations between β-blocker dosage group, predischarge heart rate group, and the primary composite outcome of death or cardiovascular rehospitalisation.

Kaplan-Meier analysis for the MACE-free or VA-free survival in patients with definite CS (A and C) or suspected CS (B and D) stratified by localisation.

Cardiovascular calcification in patients with chronic renal failure: Are we on target with this risk factor? Peter A. Mccullough, Sandeep Soman Kidney.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

(A) Quantitative plaque analysis of the RCA

Glenn N. Levine et al. JACC 2011;58:e44-e122

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Scoring of Coronary Artery Disease Characteristics on Coronary CT Angiograms by Using Machine Learning For prediction of all-cause mortality on the basis.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Genetic predisposition to CHD modifies the increased CHD risk associated with smoking (*) ORs adjusted for age, gender, total energy intake, alcohol intake,

Kaplan-Meier survival estimates for major cardiovascular events.

Kidney Injury after Intravenous versus Intra-arterial Contrast Agent in Patients Suspected of Having Coronary Artery Disease: A Randomized Trial Acute.

LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium–enhanced MRI LI-RADS version 2018 (v2018) had higher.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

A: Incidences of all-cause mortality, coronary artery events, and cerebrovascular events by quartiles of baPWV during the follow-up period. A: Incidences.

Reproducibility and Changes in Vena Caval Blood Flow by Using Four-dimensional Flow MRI in Pulmonary Emphysema and Chronic Obstructive Pulmonary Disease:

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Risk for cardiovascular disease and all-cause death according to RHR: (A) as categorical variable (HR≥75 bpm vs HR

β-Blocker Use for the Stages of Heart Failure

Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer An imaging-based predictive model.

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

Flow diagram of study conduct.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Traditional cardiovascular risk factors can cause cardiac disease in patients with IIM. Systemic and local inflammation may either have a direct effect.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Magnus Dalén, MD, Torbjörn Ivert, MD, PhD, Martin J

Presentation transcript:

Left Ventricular Mass at MRI and Long-Term Risk of Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis (MESA) Left ventricular hypertrophy (LVH) at MRI was an independent predictor of coronary heart disease events, including myocardial infarction, coronary artery disease–related death, other cardiovascular disease–related death, and heart failure (P < .001 for all end points). Over 15 years of follow-up, LVH was a stronger predictor of coronary artery disease–related death, other cardiovascular disease–related death, and heart failure than was coronary artery calcium score (z scores: 5.4 vs 3.4, 6.8 vs 2.4, and 9.7 vs 3.2, respectively). Kaplan-Meier analysis shows the cumulative incidence of hard coronary heart disease events for participants with LVH versus those without LVH. Kawel-Boehm N et al. Published Online: August 27, 2019 https://doi.org/10.1148/radiol.2019182871